Drug Profile
RPI 78
Alternative Names: RPI-78Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator ReceptoPharm
- Class Analgesics; Antirheumatics; Peptides
- Mechanism of Action Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain; Rheumatoid arthritis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Pain in USA (Parenteral, Injection)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA (Parenteral, Injection)
- 04 Feb 2021 RPI 78 is still in phase I trials for Pain and Rheumatoid arthritis in USA (ReceptoPharm pipeline, February 2021)